BSP Pharmaceuticals

Executive Summary

BSP Pharmaceuticals S.p.A. is an Italian CDMO specializing in the development and manufacturing of sterile injectable and oral dosage forms, with a strong focus on oncology, including cytotoxic, high-potent drugs, and complex modalities such as ADCs, peptides, and oligonucleotides. Founded in 2007 and based in Latina, Italy, the company offers end-to-end services from pre-clinical to commercial production, leveraging segregated, high-containment facilities to handle potent compounds safely. As the demand for targeted cancer therapies and ADCs grows, BSP is well-positioned to capture market share, particularly in Europe, by providing specialized manufacturing capabilities that many larger CDMOs lack. The company's private status allows for strategic investments in capacity expansion and technology upgrades, but limits visibility into financial performance and client relationships. However, its technical expertise and regulatory compliance position it as a key partner for biotech and pharma firms seeking reliable outsourcing for complex sterile products.

Upcoming Catalysts (preview)

• Q3 2026Completion of ADC manufacturing facility expansion75% success
• TBDAnnouncement of a long-term supply agreement with a major pharma company40% success
• Q2 2026Receipt of GMP certification for new high-potent handling line85% success